source
- Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continuesSanofi's new CEO Belén Garijo opened up for the first time about her strategy to reverse a trend of clinical setbacks, including dumping Regeneron-partnered IL-33 candidate itepekimab.Fierce Biotech · 4h ago↗ source
- J&J pays Sail $785M, charting course to possible in vivo CAR-T buyoutJohnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.Fierce Biotech · 6h ago↗ source
- FDA advisory panel rejects Capricor’s Duchenne cardiomyopathy cell therapyA FDA advisory committee voted against Capricor’s cell therapy for Duchenne muscular dystrophy cardiomyopathy, with nine members opposing and three supporting the product. The therapy, called dera…